72 ANS HBP TR 2A PSA 5.85 PIRAD 4 3 MM A 10 MM DU SPHINCTER PROSTATE 80

Clinical significance: The patient is a 72-year-old man with a prostate-specific antigen (PSA) level of 5.85 ng/mL, which is below the age-specific referral threshold of >6.5 ng/mL for men aged 70-79 years but still elevated and potentially significant given the presence of a PIRADS 4 lesion on MRI. PIRADS 4 indicates a high likelihood of clinically significant prostate cancer. The lesion size is small (3 mm), adjacent to a 10 mm sphincter prostate, with a prostate weight of 80 grams and a PSA density of 0.069 ng/mL/gram, which is below the typical cutoff of 0.15 ng/mL/gram used to raise suspicion for significant cancer. The Prostate Health Index Density (PHID) of 0.69 may further assist in risk stratification but is not routinely recommended for guiding biopsy decisions post-MRI negative or inconclusive biopsies NICE NG131,NICE CKS.

Given the presence of a PIRADS 4 lesion, the risk of clinically significant prostate cancer is increased, and an MRI-influenced prostate biopsy should be offered to establish a histological diagnosis and confirm or exclude cancer, despite the relatively low PSA density NICE NG131. The patient's age and comorbid hypertension should be considered in shared decision-making about biopsy and treatment options, balancing benefits and risks NICE CKS,NICE NG131.

Recommended management: The patient should be referred urgently to a urological specialist via the suspected cancer pathway due to the PIRADS 4 lesion and elevated PSA level to expedite further assessment and management NICE CKS,NICE CKS. A multiparametric MRI has already been performed, so a prostate biopsy targeted to the lesion should be performed unless contraindications exist NICE NG131.

If biopsy confirms cancer, management decisions—ranging from active surveillance to radical treatment—will depend on histological grade, staging, life expectancy, comorbidities (e.g., hypertension), and patient preference NICE NG131,NICE CKS. For patients with benign prostatic hyperplasia symptoms and large prostate size, medical therapy such as finasteride can be considered to reduce prostate volume and symptoms, but finasteride lowers PSA levels by approximately 50%, which must be accounted for in interpreting PSA results SmPC Finasteride,SmPC Finasteride,SmPC Proscar. Additionally, patients on finasteride require careful PSA monitoring with adjusted values and regular digital rectal examinations for prostate cancer detection SmPC Finasteride,SmPC Finasteride,SmPC Proscar.

Given the lesion location near the sphincter and prostate anatomy, surgical options would require careful imaging assessment to preserve urinary continence NICE NG131. The patient’s hypertension should be optimally controlled to reduce perioperative risks and improve overall treatment tolerance NICE CKS.